Hypereosinophilic Syndrome Pipeline Insight 2025: Pioneering Precision Approaches to Tame Eosinophilic Overactivity | DelveInsight

Hypereosinophilic Syndrome (HES) is a rare group of disorders characterized by persistently elevated eosinophil levels, often leading to end-organ damage affecting the heart, lungs, skin, and nervous system. While corticosteroids remain the mainstay of treatment, their long-term use is associated with significant toxicity. In recent years, the need for targeted, steroid-sparing therapies has driven innovation in the HES treatment landscape.

DelveInsight's "Hypereosinophilic Syndrome - Pipeline Insight, 2025" highlights a focused and promising pipeline with more than 5 emerging therapies aiming to modulate eosinophilic activity through novel mechanisms. Key therapeutic approaches include anti-IL-5 monoclonal antibodies, tyrosine kinase inhibitors (TKIs), and anti-Siglec-8 therapies, among others. Companies such as GlaxoSmithKline, Sanofi, Allakos, Revolo Biotherapeutics, and Celgene (now BMS) are actively engaged in advancing clinical candidates to offer long-term disease control and organ protection.

Notable late-stage candidates include mepolizumab, which is already approved for HES in several markets, and lirentelimab, which targets Siglec-8 to deplete eosinophils and mast cells. Additionally, next-generation TKIs are being developed for patients with FIP1L1-PDGFRA fusion and other molecularly defined subtypes. These pipeline assets reflect a broader trend towards personalized medicine in eosinophilic disorders, integrating biomarker-based patient stratification and tailored therapeutic regimens.

DelveInsight's report provides a deep dive into the mechanisms of action, clinical trial data, competitive landscape, and future outlook for HES therapies. As our understanding of eosinophil-driven pathology improves, the HES market is poised to undergo a significant transformation, shifting from generalized immunosuppression to precise, targeted interventions that improve outcomes while minimizing systemic side effects.

Interested in learning more about the current treatment landscape and the key drivers shaping the hypereosinophilic syndrome pipeline? Click here: https://www.delveinsight.com/sample-request/hypereosinophilic-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Key Takeaways from the Hypereosinophilic Syndrome Pipeline Report
• DelveInsight's hypereosinophilic syndrome pipeline analysis depicts a strong space with 5+ active players working to develop 5+ pipeline drugs for hypereosinophilic syndrome treatment.
• The leading hypereosinophilic syndrome companies include Kyowa Kirin, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Knopp Biosciences, and others are evaluating their lead assets to improve the hypereosinophilic syndrome treatment landscape.
• Key hypereosinophilic syndrome pipeline therapies in various stages of development include Benralizumab, Depemokimab, Nilotinib, Dexpramipexole, and others.
• A new Phase II study sponsored by the NIH's NIAID began on February 5, 2025, evaluating dupilumab in adult HES patients (ages 18+), including those on existing biologic therapies. The trial is set to complete primary enrollment by December 30, 2026.
• GlaxoSmithKline is running a Phase 3 study of subcutaneous mepolizumab (Nucala) in pediatric HES (ages 6-17), which began on July 11, 2022 and is projected to wrap up by October 9, 2025.
• The global Phase III "NATRON" trial of benralizumab (anti-IL‐5R) in adolescents and adults with HES began in July 2020 and is expected to conclude by November 2026. Enrollment includes ~120 participants across North America, Europe, and Asia.

Request a sample and discover the recent breakthroughs happening in the hypereosinophilic syndrome pipeline landscape at https://www.delveinsight.com/sample-request/hypereosinophilic-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Hypereosinophilic Syndrome Overview
Hypereosinophilic Syndrome (HES) is a rare group of blood disorders characterized by persistently elevated levels of eosinophils-a type of white blood cell-in the blood and tissues, leading to organ damage. Eosinophils are normally involved in immune responses, especially against parasites and in allergic reactions. In HES, however, their uncontrolled proliferation and accumulation can damage organs such as the heart, lungs, skin, liver, and nervous system.

The exact cause of HES varies, and it can be classified into several subtypes: idiopathic, myeloproliferative, and lymphocytic. Diagnosis typically involves ruling out other causes of eosinophilia and confirming sustained high eosinophil levels along with signs of tissue or organ damage. Treatments focus on reducing eosinophil levels and preventing further organ damage, often involving corticosteroids, targeted therapies like tyrosine kinase inhibitors, or biologics such as monoclonal antibodies (e.g., benralizumab) that target eosinophil pathways.

Find out more about hypereosinophilic syndrome medication at https://www.delveinsight.com/sample-request/hypereosinophilic-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Hypereosinophilic Syndrome Treatment Analysis: Drug Profile
Benralizumab: Kyowa Kirin
Benralizumab is a monoclonal antibody that triggers natural killer cells to rapidly deplete eosinophils in the blood and airways through antibody-dependent cellular cytotoxicity (ADCC). It is administered as a fixed-dose subcutaneous injection every 4 weeks for the first three doses, then every 8 weeks thereafter. Besides its current use, benralizumab is also being studied for severe nasal polyposis. The FDA has granted it orphan drug designation for hypereosinophilic syndrome (HES) and eosinophilic granulomatosis with polyangiitis (EGPA). Developed by Kyowa Kirin and AstraZeneca (licensed from BioWa, Inc., a Kyowa Hakko Kirin subsidiary), benralizumab is in Phase III clinical trials for HES.

Depemokimab: GlaxoSmithKline
Depemokimab (GSK3511294) is a humanized anti-IL-5 monoclonal antibody engineered for a longer half-life and stronger IL-5 binding compared to other anti-IL-5 antibodies. It is currently in Phase III clinical trials for the treatment of hypereosinophilic syndrome.

Learn more about the novel and emerging hypereosinophilic syndrome pipeline therapies at https://www.delveinsight.com/sample-request/hypereosinophilic-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Hypereosinophilic Syndrome Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

By Molecule Type
• Oligonucleotide
• Peptide
• Small molecule

Scope of the Hypereosinophilic Syndrome Pipeline Report
• Coverage: Global
• Key Hypereosinophilic Syndrome Companies: ERYtech Pharma, Jiangsu HengRui Medicine Co., Ltd., FibroGen, Novartis AG, AB Science, Eleison Pharmaceuticals, Cornerstone Pharmaceuticals, Panbela Therapeutics, Taiho Pharmaceutical Co., Ltd., Rain Oncology, Redx Pharma Plc, Eli Lilly and Company, Jazz Pharmaceuticals, Immodulon Therapeutics Ltd, GSK, Merck Sharp & Dohme LLC, Roche, Helsinn Healthcare SA, DEKA Biosciences, Senhwa Biosciences, Cue Biopharma, Carisma Therapeutics Inc, ChemoCentryx, Boehringer Ingelheim, Bicara Therapeutics, Arcus Biosciences, Mainline Biosciences, Beijing Imunopharm Technology Co., Ltd., TriSalus Life Sciences, Ono Pharmaceutical, Exelixis, Wellmaker Bio, Pionyr Immunotherapeutics, Ability Pharmaceuticals SL, A2 Biotherapeutics, Klus Pharma Inc., Nelum Corp, Crystal Genomics Inc., Elicio Therapeutics, Turning Point Therapeutics, Immuneering Corporation, pHion Therapeutics Ltd., AC BioScience, TheraVectys, Opna Bio, Cytuvax, Eureka Therapeutics, and others.
• Key Hypereosinophilic Syndrome Pipeline Therapies: Eryaspase, Fuzuloparib, Pamrevlumab, NIS793, Masitinib, Glufosfamide, Devimistat, SBP-101, TAS-102, RAIN-32, RXC004, LY3214996, Lurbinectedin, IMM-101, GSK2256098, Belzutifan, Atezolizumab, Anamorelin, DK210, CX-5461, CUE-102, CT-0508, CCX872-B, BI 765049, BCA101, AB680, MB1707, IM96 CAR-T cells, SD-101, ONO 7913, PY159, XL888, WM-S1-030, ABTL0812, A2B530, A166, NLM-001, Ivaltinostat, ELI-002, TPX4589, IMM-1-104, PTX_C1, ACB2003.4, Research program, OPN-FMRP, PanCaVax - Hypereosinophilic Syndrome Vaccine, Research Program 2, and others.

To dive deep into rich insights for drugs used for hypereosinophilic syndrome treatment, visit: https://www.delveinsight.com/sample-request/hypereosinophilic-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Hypereosinophilic Syndrome Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Hypereosinophilic Syndrome Pipeline Therapeutics
6. Hypereosinophilic Syndrome Pipeline: Late-Stage Products (Phase III)
7. Hypereosinophilic Syndrome Pipeline: Mid-Stage Products (Phase II)
8. Hypereosinophilic Syndrome Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.